RayKnowChina Research Map
Shortlist

RecruitingBreast cancerN/A

Registered title, quoted from ClinicalTrials.gov

Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  2. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04158843, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed breast cancer and after radical mastectomy

    Inclusion criterion 3

  3. Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade = 1 from any acute CTCAE v. 5.0 grade =2 side effects of previous treatments

    Inclusion criterion 5

    Active infection with human immunodeficiency virus (HIV) prior to first study treatment administration.

    Exclusion criterion 6

  4. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2

    Inclusion criterion 12

  5. Alanine aminotransferase (ALT) </= 2.5 × the upper limit of normal (ULN), Aspartate aminotransferase (AST) </= 2.5 × ULN prior to randomization

    Inclusion criterion 7

    Total bilirubin (TBIL) </= 1.25 × ULN

    Inclusion criterion 8

    Alkaline phosphatase (ALK) </= 2.5 × ULN

    Inclusion criterion 9

    Gamma glutamyl transpeptidase (GGT) </= 2.5 × ULN

    Inclusion criterion 10

    Serum total bilirubin (TBil) </= 1.5 × ULN

    Inclusion criterion 14

    Serum creatinine (Scr) </= 1.5 × ULN

    Inclusion criterion 15

    White blood cell count (WBC) >/= 3×109/L, Blood neutrophil count >/= 1.5×109/L, Platelet count >/= 100×109/L, Hemoglobin (HB) >/= 9 g/dL

    Inclusion criterion 16

  6. Pregnancy or lactation

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04158843, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients provided written informed consent
  • Women aged 18-75 years old
  • Histologically confirmed breast cancer and after radical mastectomy
  • Patients of breast cancer with ipsilateral humerus or sternum oligometastasis, and there is no imaging evidence of other site metastases
  • Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade = 1 from any acute CTCAE v. 5.0 grade =2 side effects of previous treatments
  • Without infection of human immunodeficiency virus (HIV) on central laboratory assay results prior to randomization
  • Alanine aminotransferase (ALT) </= 2.5 × the upper limit of normal (ULN), Aspartate aminotransferase (AST) </= 2.5 × ULN prior to randomization
  • Total bilirubin (TBIL) </= 1.25 × ULN
  • Alkaline phosphatase (ALK) </= 2.5 × ULN
  • Gamma glutamyl transpeptidase (GGT) </= 2.5 × ULN
  • Albumin >/= 30g/L
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
  • Women of child-bearing age should take effective contraceptive measures
  • Serum total bilirubin (TBil) </= 1.5 × ULN
  • Serum creatinine (Scr) </= 1.5 × ULN
  • White blood cell count (WBC) >/= 3×109/L, Blood neutrophil count >/= 1.5×109/L, Platelet count >/= 100×109/L, Hemoglobin (HB) >/= 9 g/dL

Exclusion Criteria:

  • Without radical mastectomy of the primary breast lesions
  • No radical resection or radiotherapy is possible for metastatic lesions
  • Other site metastases except ipsilateral humerus or sternum are present
  • With multiple metastatic lesions
  • Any other current malignancy or malignancy diagnosed within the past five years (other than carcinoma in situ or stage Ia carcinoma of the cervix, skin basal cell carcinoma and papillary thyroid carcinoma at early stage)
  • Active infection with human immunodeficiency virus (HIV) prior to first study treatment administration.
  • History of participating any other clinical trials within 30 days prior to randomization
  • Known unable to tolerate humerus or sternal surgery or radical radiotherapy
  • Pregnancy or lactation
  • Current severe systemic disease (for example, clinically significant cardiovascular, pulmonary, or renal disease)
  • Legal incompetence or limitation.
  • Considered unable to complete the study or sign the informed consent due to a medical or mental disorder by the investigator.

Quoted from ClinicalTrials.gov, NCT04158843, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04158843, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04158843